A comparison of two stocks would show that currently IONS has a market cap of around $7.4 billion and ARNA at $2.4 billion and both have a nice bank account...
IONS currently collects royalties for Spinraza to the tune of around 15% or perhaps a few hundred million annually as their only worthwhile drug mentioning as those at AKCA are mostly showing to be duds so far...
Etrasimod at $7.5 billion in potential revenue (his number) is unheard of and is such a tempting target for all the BP's to want so one would expect that if the trials pan out as this analysts and others think the stock is heading much higher then his target.
Imo, this company would get bought out and a triple digit number would be in the area it would take to get it..... Just so you know it took $6.5 billion to get Receptus in a buyout..you do the math...